MyOme Proactive Health is a clinical whole genome testing platform that helps employers identify hereditary disease risk in their employees — years before symptoms develop. Using whole genome sequencing and AI-integrated polygenic risk modeling, MyOme delivers actionable reports covering hereditary cancer risk (including BRCA-linked breast, ovarian, and colon cancer, Lynch syndrome, and others), cardiovascular disease, medication response (pharmacogenomics), and additional hereditary conditions across a single saliva sample.
Unlike traditional genetic panels that test for limited gene variants, MyOme's whole genome approach analyzes an individual's complete genetic blueprint — producing a lifetime of clinically actionable insights that can be reinterpreted as science evolves, without requiring a new sample.
For employers, MyOme Proactive Health enables a shift from reactive, claims-driven healthcare to proactive, prevention-focused benefit design. Employees who learn of elevated hereditary risk can pursue earlier screening, preventive interventions, and lifestyle changes — reducing downstream claims costs while improving health outcomes. All genomic data is owned by the individual, is never shared with employers or health plans without explicit consent, and is protected under HIPAA and GINA.
Claimed
